Annual Current Liabilities
$327.92 M
+$188.47 M+135.15%
December 31, 2022
Summary
- As of February 23, 2025, SRNE annual total current liabilities is $327.92 million, with the most recent change of +$188.47 million (+135.15%) on December 31, 2022.
- During the last 3 years, SRNE annual current liabilities has risen by +$212.72 million (+184.64%).
- SRNE annual current liabilities is now at all-time high.
Performance
SRNE Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$264.95 M
+$99.32 M+59.96%
June 30, 2023
Summary
- As of February 23, 2025, SRNE quarterly total current liabilities is $264.95 million, with the most recent change of +$99.32 million (+59.96%) on June 30, 2023.
- Over the past year, SRNE quarterly current liabilities has increased by +$99.32 million (+59.96%).
- SRNE quarterly current liabilities is now -19.20% below its all-time high of $327.92 million, reached on December 31, 2022.
Performance
SRNE Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
SRNE Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +135.2% | +60.0% |
| 3 y3 years | +184.6% | +60.0% |
| 5 y5 years | +315.3% | +60.0% |
SRNE Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +135.2% | -19.2% | +90.0% |
| 5 y | 5-year | at high | +239.9% | -19.2% | +193.9% |
| alltime | all time | at high | >+9999.0% | -19.2% | -100.0% |
Sorrento Therapeutics Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2023 | - | $264.95 M(+60.0%) |
| Mar 2023 | - | $165.63 M(-49.5%) |
| Dec 2022 | $327.92 M(+135.1%) | $327.92 M(+62.4%) |
| Sep 2022 | - | $201.98 M(+39.0%) |
| Jun 2022 | - | $145.32 M(-28.8%) |
| Mar 2022 | - | $204.23 M(+46.5%) |
| Dec 2021 | $139.45 M(+44.5%) | $139.45 M(-20.4%) |
| Sep 2021 | - | $175.18 M(-2.9%) |
| Jun 2021 | - | $180.45 M(+87.9%) |
| Mar 2021 | - | $96.04 M(-0.5%) |
| Dec 2020 | $96.48 M(-16.3%) | $96.48 M(+4.7%) |
| Sep 2020 | - | $92.13 M(+0.9%) |
| Jun 2020 | - | $91.34 M(+1.3%) |
| Mar 2020 | - | $90.15 M(-21.8%) |
| Dec 2019 | $115.21 M(+87.0%) | $115.21 M(+2.2%) |
| Sep 2019 | - | $112.71 M(+0.6%) |
| Jun 2019 | - | $111.99 M(+51.2%) |
| Mar 2019 | - | $74.08 M(+20.2%) |
| Dec 2018 | $61.62 M(-22.0%) | $61.62 M(-25.2%) |
| Sep 2018 | - | $82.41 M(+109.2%) |
| Jun 2018 | - | $39.40 M(-23.5%) |
| Mar 2018 | - | $51.52 M(-34.7%) |
| Dec 2017 | $78.95 M(+3.8%) | $78.95 M(-5.3%) |
| Sep 2017 | - | $83.35 M(+5.1%) |
| Jun 2017 | - | $79.28 M(+10.4%) |
| Mar 2017 | - | $71.83 M(-5.6%) |
| Dec 2016 | $76.08 M(+146.4%) | $76.08 M(+111.1%) |
| Sep 2016 | - | $36.04 M(-40.9%) |
| Jun 2016 | - | $61.03 M(+114.7%) |
| Mar 2016 | - | $28.43 M(-7.9%) |
| Dec 2015 | $30.87 M(+223.0%) | $30.87 M(+18.4%) |
| Sep 2015 | - | $26.07 M(+151.6%) |
| Jun 2015 | - | $10.36 M(+10.2%) |
| Mar 2015 | - | $9.40 M(-1.6%) |
| Dec 2014 | $9.56 M(+74.4%) | $9.56 M(+9.8%) |
| Sep 2014 | - | $8.70 M(+26.0%) |
| Jun 2014 | - | $6.91 M(+31.6%) |
| Mar 2014 | - | $5.25 M(-4.2%) |
| Dec 2013 | $5.48 M | $5.48 M(+136.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2013 | - | $2.32 M(+56.2%) |
| Jun 2013 | - | $1.48 M(+17.2%) |
| Mar 2013 | - | $1.27 M(+116.7%) |
| Dec 2012 | $584.20 K(+62.6%) | $584.20 K(+7.4%) |
| Sep 2012 | - | $544.20 K(+30.9%) |
| Jun 2012 | - | $415.70 K(+29.9%) |
| Mar 2012 | - | $320.00 K(-10.9%) |
| Dec 2011 | $359.30 K(-40.5%) | $359.30 K(-23.9%) |
| Sep 2011 | - | $472.00 K(+11.1%) |
| Jun 2011 | - | $425.00 K(-61.9%) |
| Mar 2011 | - | $1.12 M(+84.8%) |
| Dec 2010 | $604.00 K(+71.1%) | $604.00 K(+42.6%) |
| Sep 2010 | - | $423.50 K(+83.3%) |
| Jun 2010 | - | $231.10 K(+25.1%) |
| Mar 2010 | - | $184.70 K(-47.7%) |
| Dec 2009 | $353.10 K(+200.8%) | $353.10 K(+63.8%) |
| Sep 2009 | - | $215.60 K(+467.4%) |
| Jun 2009 | - | $38.00 K(-0.3%) |
| Mar 2009 | - | $38.10 K(-67.5%) |
| Dec 2008 | $117.40 K(+3457.6%) | $117.40 K(>+9900.0%) |
| Sep 2008 | - | $200.00(>+9900.0%) |
| Jun 2008 | - | $0.00(-100.0%) |
| Mar 2008 | - | $11.70 K(+254.5%) |
| Dec 2007 | $3300.00(-99.3%) | $3300.00(-17.5%) |
| Sep 2007 | - | $4000.00(-75.8%) |
| Jun 2007 | - | $16.50 K(-54.9%) |
| Mar 2007 | - | $36.60 K(-92.2%) |
| Dec 2006 | $471.80 K(+1351.7%) | $471.80 K(+1351.7%) |
| Sep 2006 | - | $32.50 K(0.0%) |
| Jun 2006 | - | $32.50 K(0.0%) |
| Mar 2006 | - | $32.50 K(0.0%) |
| Dec 2005 | $32.50 K(-90.5%) | $32.50 K(-90.5%) |
| Sep 2005 | - | $341.10 K(+0.1%) |
| Jun 2005 | - | $340.90 K(+0.1%) |
| Mar 2005 | - | $340.70 K(+0.1%) |
| Dec 2004 | $340.50 K(+0.2%) | $340.50 K(+0.1%) |
| Sep 2004 | - | $340.30 K(+0.0%) |
| Jun 2004 | - | $340.20 K(+0.1%) |
| Mar 2004 | - | $340.00 K |
| Dec 2003 | $339.80 K | - |
FAQ
- What is Sorrento Therapeutics annual total current liabilities?
- What is the all time high annual current liabilities for Sorrento Therapeutics?
- What is Sorrento Therapeutics annual current liabilities year-on-year change?
- What is Sorrento Therapeutics quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Sorrento Therapeutics?
- What is Sorrento Therapeutics quarterly current liabilities year-on-year change?
What is Sorrento Therapeutics annual total current liabilities?
The current annual current liabilities of SRNE is $327.92 M
What is the all time high annual current liabilities for Sorrento Therapeutics?
Sorrento Therapeutics all-time high annual total current liabilities is $327.92 M
What is Sorrento Therapeutics annual current liabilities year-on-year change?
Over the past year, SRNE annual total current liabilities has changed by +$188.47 M (+135.15%)
What is Sorrento Therapeutics quarterly total current liabilities?
The current quarterly current liabilities of SRNE is $264.95 M
What is the all time high quarterly current liabilities for Sorrento Therapeutics?
Sorrento Therapeutics all-time high quarterly total current liabilities is $327.92 M
What is Sorrento Therapeutics quarterly current liabilities year-on-year change?
Over the past year, SRNE quarterly total current liabilities has changed by +$99.32 M (+59.96%)